Grid Therapeutics, another Triangle company working on a promising anti-cancer immunotherapy, has raised a chunk of a combined debt and equity round. Its first treatment offers hope to certain small cell lung cancer patients who have had the disease recurr.
Read More
Grid Therapeutics has received clearance from the U.S. Food and Drug Administration to begin human testing of its new cancer immunotherapy.
Read More
DURHAM — Grid Therapeutics Inc., an emerging biotechnology company, has the exclusive rights to a novel antibody for the treatment of lung cancer with application in multiple cancer types. The initial discovery was made by Edward Patz Jr. in his laboratory at Duke University Medical Center. This antibody discovered...
Read More
Grid Therapeutics, a Durham-based biotechnology company developing the first human derived targeted immunotherapy for cancer, has raised more than $4.5 million of a $5 million equity offering, according to a filing with the U.S. Securities and Exchange Commission.
Read More
